单位：
南方医科大学药学院
学科领域：
药学
研究兴趣：
主要从事基础神经药理学研究及新药临床前评价
评价数量
2发文量
100+H指数
个人简介
南方医科大学药学二级岗教授，从事神经精神药理和新药创制研究近30年；担任CDE药审中心药物审批审评专家近20年，完成临床前并成功上市或进入临床的药物研发项目超过40项，曾担任舒泰神（北京）生物制药股份有限公司研发副总经理，组建研发团队并推进多个项目进入临床研究。主持并完成科技部“重大新药创制”项目两项。2016年作为创始人成立兰晟医药，专注于中枢神经系统领域的新药及高端制剂研发，以“深入的靶点覆盖”加“系列创新药”为研发策略，构建中德法三国合作的高端制剂平台及全球化合作布局，引领公司持续发展，已到位融资款数亿元。2019年荣获苏州工业园区“金鸡湖科技领军人才“荣誉奖项。
社会任职
国家自然科学基金委员会函审二审专家；
中国卒中学会新药研发与评价委员会副主任委员；
国家食品药品监督管理局保健食品评审专家委员会委员；
国家食品药品监督管理局新药评审专家委员会委员；
中国药理学会神经精神药理学专业委员会常务委员；
中国药理学会抗衰老与老年痴呆专业委员会常务委员；
中国药理学会教学及科普专业委员会常务委员；
广东省药理学会常务理事；
广东省药理学会神经药理学专业委员会荣誉主任委员；
学术贡献
主要从事基础神经药理学研究及新药临床前评价，研究方向为1. 治疗神经精神疾病药物新靶点的创新药物设计与活性评价；2. 神经精神疾病（AD、PD、脑缺血、抑郁症等）的发病机理研究和药物筛选；3. 抗神经退行性疾病的中药成分及其机制研究。近5年以第一/通讯作者论文发表在Redox Biology、Brain Behav Immun、FASEB J、BJP、Neuropharmacology、Psychopharmacology等主流学术刊物上。先后主持国家自然科学基金8项，国家新药创制重大专项2项、省市课题20余项。主持1类抗帕金森病新药的I，II期临床试验；获广东省高等学校“千百十工程”国家级培养对象及广东省科学技术奖励等。
工作经历
2019/12-至今： 南方医科大学药学院神经系统与代谢疾病药物研究群体 学术负责人
2015/07-2020/05：南方医科大学中心实验室，主任
2012-2016：舒泰神（北京）生物制药股 份有限公司，研发总监，副总经理（兼职）
2010/01-至今：南方医科大学药学院，教授，博士生导师；先后担任神经药理学科主任(PI)、药学系主任、神经药理及新药发现学科PI
2005/12- 2009/12： 南方医科大学药学院，教授，药理学系主任，博士生导师
2005/07-2005/11：南方医科大学药学院，副教授，药理教研室主任
2004/08-2005/06：南方医科大学基础部，副教授，药理教研室主任
2002/10-2004/08：第一军医大学基础部，副教授，药理教研室主任
1999/10-2002/09：第一军医大学，基础部，副教授
教育经历
1985.09-1990.07 第一军医大学，军医系, 学士
1990.09-1993.07 军事医学科学院毒物药物研究所, 药理学，硕士
1993.09-1997.07 军事医学科学院毒物药物研究所，药理学，博士
1997.08-1999.09 第二军医大学药学院，药学博士后
代表作品
(1) Xia, C.; Wen, H.; Zheng, L.; Ni, Y.; Bi, H.; Wang, H.; Xu, J.; Zhou, Z.-Z. Discovery of 7-Alkoxybenzofurans as PDE4 Inhibitors with Hepatoprotective Activity in D-GalN/LPS-Induced Hepatic Sepsis. Eur J Med Chem 2024, 275, 116576. https://doi.org/10.1016/j.ejmech.2024.116576.
(2) Chen, K.; Xu, B.; Qiu, S.; Long, L.; Zhao, Q.; Xu, J.; Wang, H. Inhibition of Phosphodiesterase 4 Attenuates Aquaporin 4 Expression and Astrocyte Swelling Following Cerebral Ischemia/Reperfusion Injury. Glia 2024, 72 (9), 1629–1645. https://doi.org/10.1002/glia.24572.
(3) Chen, K.; Xu, B.; Long, L.; Wen, H.; Zhao, Q.; Tu, X.; Wang, J.; Xu, J.; Wang, H. Inhibition of Phosphodiesterase 4 Suppresses Neuronal Ferroptosis After Cerebral Ischemia/Reperfusion. Mol Neurobiol 2024. https://doi.org/10.1007/s12035-024-04495-9.
(4) Chen, K.; Xu, B.; Xiao, X.; Long, L.; Zhao, Q.; Fang, Z.; Tu, X.; Wang, J.; Xu, J.; Wang, H. Involvement of CKS1B in the Anti-Inflammatory Effects of Cannabidiol in Experimental Stroke Models. Exp Neurol 2024, 373, 114654. https://doi.org/10.1016/j.expneurol.2023.114654.
(5) Chen, K.; Xu, B.; Xiao, X.; Long, L.; Zhao, Q.; Fang, Z.; Tu, X.; Wang, J.; Xu, J.; Wang, H. Involvement of CKS1B in the Anti-Inflammatory Effects of Cannabidiol in Experimental Stroke Models. Experimental Neurology 2024, 373, 114654. https://doi.org/10.1016/j.expneurol.2023.114654.
(6) Qiu, S.; Xian, Z.; Chen, J.; Huang, P.; Wang, H.; Wang, H.; Xu, J. Microglia Nuclear Receptor Corepressor 1 Deficiency Alleviates Neuroinflammation in Mice. Neuroscience Letters 2024, 822, 137643. https://doi.org/10.1016/j.neulet.2024.137643.
(7) Xu, B.; Liu, Z.; Chen, K.; Zhao, Q.; Wen, H.; Lin, J.; Xu, J.; Wang, H.; Wang, H.; Wang, Y. Mitofusin 2 Mediates the Protective Effect of NR6A1 Silencing Against Neuronal Injury in Experimental Stroke Models. Mol Neurobiol 2024. https://doi.org/10.1007/s12035-024-04466-0.
(8) Li, X.; Xu, B.; Long, L.; Li, Y.; Xiao, X.; Qiu, S.; Xu, J.; Tian, L.-W.; Wang, H. Phelligridimer A Enhances the Expression of Mitofusin 2 and Protects against Cerebral Ischemia/Reperfusion Injury. Chem Biol Interact 2024, 398, 111090. https://doi.org/10.1016/j.cbi.2024.111090.
(9) Niu, B.; Zhao, M.; Gao, X.; Xu, J.; Yu, L. TMT-Based Quantitative Proteomics Analysis of Neuroprotective Effects of Forsythoside A on the MPTP-Induced Parkinson’s Disease Mouse Model. Exp Neurol 2024, 373, 114642. https://doi.org/10.1016/j.expneurol.2023.114642.
(10) Huang, J.-X.; Zhu, B.-L.; Xu, J.-P.; Zhou, Z.-Z. Advances in the Development of Phosphodiesterase 7 Inhibitors. Eur J Med Chem 2023, 250, 115194. https://doi.org/10.1016/j.ejmech.2023.115194.
(11) Jiang, H.; Li, X.; Xing, Z.; Niu, Q.; Xu, J. Intracellular Activity of Poly (DL-Lactide-Co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant Mycobacterium Tuberculosis. Curr Drug Deliv 2023, 20 (3), 306–316. https://doi.org/10.2174/1567201819666220511120215.
(12) Huang, P.; Wei, S.; Ren, J.; Tang, Z.; Guo, M.; Situ, F.; Zhang, D.; Zhu, J.; Xiao, L.; Xu, J.; Liu, G. MicroRNA-124-3p Alleviates Cerebral Ischaemia-Induced Neuroaxonal Damage by Enhancing Nrep Expression. J Stroke Cerebrovasc Dis 2023, 32 (2), 106949. https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106949.
(13) Xu, B.-T.; Li, M.-F.; Chen, K.-C.; Li, X.; Cai, N.-B.; Xu, J.-P.; Wang, H.-T. Mitofusin-2 Mediates Cannabidiol-Induced Neuroprotection against Cerebral Ischemia in Rats. Acta Pharmacol Sin 2023, 44 (3), 499–512. https://doi.org/10.1038/s41401-022-01004-3.
(14) Liu, J.; Liu, L.; Zheng, L.; Feng, K.-W.; Wang, H.-T.; Xu, J.-P.; Zhou, Z.-Z. Discovery of Novel 2,3-Dihydro-1H-Inden-1-Ones as Dual PDE4/AChE Inhibitors with More Potency against Neuroinflammation for the Treatment of Alzheimer’s Disease. Eur J Med Chem 2022, 238, 114503. https://doi.org/10.1016/j.ejmech.2022.114503.
(15) Xia, C.; He, J.-P.; Feng, K.-W.; Liu, L.; Zheng, L.; Wang, H.-T.; Xu, J.-P.; Zhou, Z.-Z. Discovery of Novel 3-Amino-4-Alkoxyphenylketones as PDE4 Inhibitors with Improved Oral Bioavailability and Safety against Spatial Memory Impairments. ACS Chem Neurosci 2022, 13 (3), 390–405. https://doi.org/10.1021/acschemneuro.1c00762.
(16) Ren, J.; Li, C.; Wei, S.; He, Y.; Huang, P.; Xu, J. Identifying Antidepressant Effects of Brain-Derived Neurotrophic Factor and IDO1 in the Mouse Model Based on RNA-Seq Data. Front Genet 2022, 13, 890961. https://doi.org/10.3389/fgene.2022.890961.
(17) Li, M.; Xu, B.; Li, X.; Li, Y.; Qiu, S.; Chen, K.; Liu, Z.; Ding, Y.; Wang, H.; Xu, J.; Wang, H. Mitofusin 2 Confers the Suppression of Microglial Activation by Cannabidiol: Insights from in Vitro and in Vivo Models. Brain Behav Immun 2022, 104, 155–170. https://doi.org/10.1016/j.bbi.2022.06.003.
(18) Yu, H.; Shao, S.; Xu, J.; Guo, H.; Zhong, Z.; Xu, J. Persimmon Leaf Extract Alleviates Chronic Social Defeat Stress-Induced Depressive-like Behaviors by Preventing Dendritic Spine Loss via Inhibition of Serotonin Reuptake in Mice. Chin Med 2022, 17 (1), 65. https://doi.org/10.1186/s13020-022-00609-4.
(19) Liu, H.; Deng, B.; Zhou, H.; Wu, Z.; Chen, Y.; Weng, G.; Zhu, S.; Xu, J.; Wang, H.; Zhou, Z.; Tan, E.-K.; Wang, Q. QEEG Indices Are Associated with Inflammatory and Metabolic Risk Factors in Parkinson’s Disease Dementia: An Observational Study. EClinicalMedicine 2022, 52, 101615. https://doi.org/10.1016/j.eclinm.2022.101615.
(20) Cai, N.; Xu, B.; Li, X.; Qin, Y.; Li, M.; Chen, K.; Xu, J.; Wang, H. Roflumilast, a Cyclic Nucleotide Phosphodiesterase 4 Inhibitor, Protects against Cerebrovascular Endothelial Injury Following Cerebral Ischemia/Reperfusion by Activating the Notch1/Hes1 Pathway. Eur J Pharmacol 2022, 926, 175027. https://doi.org/10.1016/j.ejphar.2022.175027.
(21) Zhong, J.; Li, M.; Xu, J.; Dong, W.; Qin, Y.; Qiu, S.; Li, X.; Wang, H. Roflupram Attenuates α-Synuclein-Induced Cytotoxicity and Promotes the Mitochondrial Translocation of Parkin in SH-SY5Y Cells Overexpressing A53T Mutant α-Synuclein. Toxicol Appl Pharmacol 2022, 436, 115859. https://doi.org/10.1016/j.taap.2021.115859.
(22) Chen, Y.; Shen, M.; Liu, X.; Xu, J.; Wang, C. The Regulation of Glutamate Transporter 1 in the Rapid Antidepressant-Like Effect of Ketamine in Mice. Front Behav Neurosci 2022, 16, 789524. https://doi.org/10.3389/fnbeh.2022.789524.
(23) Gong, W.; Luo, C.; Peng, F.; Xiao, J.; Zeng, Y.; Yin, B.; Chen, X.; Li, S.; He, X.; Liu, Y.; Cao, H.; Xu, J.; Long, H. Brahma-Related Gene-1 Promotes Tubular Senescence and Renal Fibrosis through Wnt/β-Catenin/Autophagy Axis. Clin Sci (Lond) 2021, 135 (15), 1873–1895. https://doi.org/10.1042/CS20210447.
(24) Liu, J.; Ye, W.; Xu, J.-P.; Wang, H.-T.; Li, X.-F.; Wang, W.-Y.; Zhou, Z.-Z. Discovery of Novel Trimethoxyphenylbenzo[d]Oxazoles as Dual Tubulin/PDE4 Inhibitors Capable of Inducing Apoptosis at G2/M Phase Arrest in Glioma and Lung Cancer Cells. Eur J Med Chem 2021, 224, 113700. https://doi.org/10.1016/j.ejmech.2021.113700.